Clinically Relevant Risk of Hepatitis B Virus Infection and Reactivation in People with HIV After Withdrawal of Anti-HBV–Active Antiretroviral Therapy in Japan
Open Forum Infectious Diseases·
- DOI
- 10.1093/ofid/ofag533
- PMID
- —
- PMCID
- —
- OpenAlex
- —
- Study type
- Cohort study
- Publisher
- Oxford University Press (OUP)
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The data underscore potential vulnerabilities in viral containment when standard prophylactic medication elements are removed from ongoing care plans. These observations may assist health authorities in refining monitoring protocols for patient populations transitioning between therapeutic strategies in areas where population-level immunization coverage remains incomplete.
Structured evidence summary
Research question
The investigation sought to quantify the probability of acquiring or experiencing a resurgence of hepatitis B virus among individuals living with human immunodeficiency virus once they discontinue antiretroviral protocols containing specific antiviral components.
Study design
Researchers employed a retrospective observational framework centered at a single medical institution to track participant outcomes over an extended timeline.
Population and setting
The cohort comprised patients managing human immunodeficiency virus at a Japanese healthcare facility. Participants were monitored while receiving treatment regimens that excluded specific nucleoside analogues known to suppress hepatitis B replication.
Main findings
Five hepatitis B-related occurrences were documented across the observation window. The calculated occurrence rate reached 0.70 per one hundred person-years overall, climbing to 1.28 per one hundred person-years for participants lacking protective surface antibodies. Survival analysis demonstrated a statistically significant reduction in complication-free duration for antibody-negative subjects compared to those with existing immunity.
Public-health relevance
The data underscore potential vulnerabilities in viral containment when standard prophylactic medication elements are removed from ongoing care plans. These observations may assist health authorities in refining monitoring protocols for patient populations transitioning between therapeutic strategies in areas where population-level immunization coverage remains incomplete.
Important limitations
This assessment depends entirely on the provided abstract and associated metadata, requiring access to the complete manuscript for decision-grade interpretation. Furthermore, the retrospective methodology and single-institution recruitment strategy inherently constrain the broader applicability of the observed rates.
GIDS interpretation
This publication offers contextual reference material regarding viral dynamics following therapeutic modifications within a defined regional healthcare environment. It functions as a historical benchmark for understanding past treatment transitions rather than reflecting current real-time epidemiological monitoring.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 11 auditable classifier relationships to diseases, places, topics, and study design.